{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:55:04Z","timestamp":1785876904790,"version":"3.56.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173850"],"award-info":[{"award-number":["82173850"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573612"],"award-info":[{"award-number":["82573612"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bbadis.2026.168324","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T06:46:13Z","timestamp":1781592373000},"page":"168324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Synergistic apoptosis-sensitizing effect of PD-L1 inhibitor ARB-272572 encapsulated in TRAIL-expressing extracellular vesicles for renal cell carcinoma therapy"],"prefix":"10.1016","volume":"1872","author":[{"given":"Ronghui","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanjiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiubin","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyi","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiyao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menglin","family":"Hai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengqiang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bbadis.2026.168324_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bbadis.2026.168324_bb0010","first-page":"54","article-title":"Recent progress on tyrosine kinase inhibitors resistance in renal cell carcinoma: another brick in the wall?","volume":"8","author":"Dong","year":"2025","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.bbadis.2026.168324_bb0015","article-title":"Advances in immunotherapy and targeted therapy for advanced clear-cell renal cell carcinoma: current strategies and future directions","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbadis.2026.168324_bb0020","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jconrel.2024.06.048","article-title":"Auto-loaded TRAIL-exosomes derived from induced neural stem cells for brain cancer therapy","volume":"372","author":"Zhang","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbadis.2026.168324_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.126031","article-title":"Current approaches overcome the limit of TRAIL-based treatment in colorectal cancer: from fusion protein to nano-delivery platform","volume":"683","author":"Chen","year":"2025","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.bbadis.2026.168324_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.acthis.2025.152270","article-title":"Exosomal delivery of AZD5582 to overcome TRAIL resistance as an optimal therapy against triple-negative breast cancer","volume":"127","author":"Zhang","year":"2025","journal-title":"Acta Histochem."},{"issue":"5","key":"10.1016\/j.bbadis.2026.168324_bb0035","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3390\/cancers12051157","article-title":"Extracellular vesicle delivery of TRAIL eradicates resistant tumor growth in combination with CDK inhibition by dinaciclib","volume":"12","author":"Ke","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.bbadis.2026.168324_bb0040","article-title":"Enhanced anticancer efficacy of TRAIL-conjugated and odanacatib-loaded PLGA nanoparticles in TRAIL resistant cancer","volume":"312","author":"Nguyen","year":"2024","journal-title":"Biomaterials"},{"issue":"6","key":"10.1016\/j.bbadis.2026.168324_bb0045","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2025.5753","article-title":"Chaetocin enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis by enhancing DR5 stabilization and reactive oxygen species generation in human glioblastoma cells","volume":"66","author":"Jung","year":"2025","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bbadis.2026.168324_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117382","article-title":"Discovery of potent quinone oxidoreductase 2 inhibitors to overcome TRAIL resistance of non-small cell lung cancer","volume":"288","author":"Qi","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bbadis.2026.168324_bb0055","article-title":"Extracellular vesicle-mediated co-delivery of TRAIL and dinaciclib for targeted therapy of resistant tumors","volume":"10","author":"Changhong","year":"2022","journal-title":"Biomater. Sci."},{"issue":"7\u20138","key":"10.1016\/j.bbadis.2026.168324_bb0060","first-page":"1060","article-title":"Selective CDK9 knockdown sensitizes TRAIL response by suppression of antiapoptotic factors and NF-kappaB pathway","volume":"28","author":"Qian","year":"2023","journal-title":"Apoptosis"},{"issue":"1","key":"10.1016\/j.bbadis.2026.168324_bb0065","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12645-025-00329-y","article-title":"Exosomal encapsulation of a steviol derivative SD9 to overcome TRAIL resistance as a highly effective therapy against lung cancer","volume":"16","author":"Li","year":"2025","journal-title":"Cancer Nanotechnol."},{"issue":"10","key":"10.1016\/j.bbadis.2026.168324_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00210-025-04208-6","article-title":"Combination therapies and novel delivery systems: a new frontier in overcoming TRAIL resistance in gastric cancer","volume":"398","author":"Rodrigues","year":"2025","journal-title":"Naunyn Schmiedeberg\u2019s Arch. Pharmacol."},{"issue":"8","key":"10.1016\/j.bbadis.2026.168324_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12015-025-10979-5","article-title":"The advantages of mesenchymal stem cell-derived extracellular vesicles as drug delivery systems","volume":"21","author":"Kuang","year":"2025","journal-title":"Stem Cell Rev. Rep."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168324_bb0080","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3892\/ol.2022.13596","article-title":"Research progress on the intrinsic non-immune function of PD-L1 in tumors (review)","volume":"25","author":"Deng","year":"2023","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168324_bb0085","doi-asserted-by":"crossref","first-page":"9080","DOI":"10.1038\/s41467-025-64149-9","article-title":"Munc13-4 mediates tumor immune evasion by regulating the sorting and secretion of PD-L1 via exosomes","volume":"16","author":"Liu","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168324_bb0090","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Ming","year":"2022","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bbadis.2026.168324_bb0095","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s12943-025-02400-z","article-title":"Overcoming resistance to anti-PD-L1 immunotherapy: mechanisms, combination strategies, and future directions","volume":"24","author":"Mandal","year":"2025","journal-title":"Mol. Cancer"},{"issue":"11","key":"10.1016\/j.bbadis.2026.168324_bb0100","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.7150\/jca.108163","article-title":"Strategies to overcome PD-1\/PD-L1 blockade resistance: focusing on combination with immune checkpoint blockades","volume":"16","author":"Liu","year":"2025","journal-title":"J. Cancer"},{"key":"10.1016\/j.bbadis.2026.168324_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115555","article-title":"Overcoming resistance to PD-1 inhibitors: the synergistic anti-tumor effect with inflammatory factors","volume":"166","author":"Yan","year":"2025","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"10.1016\/j.bbadis.2026.168324_bb0110","first-page":"135","article-title":"Regulation of programmed death ligand 1 (PD-L1) expression by TNF-related apoptosis-inducing ligand (TRAIL) in triple-negative breast cancer cells","volume":"62","author":"M.","year":"2022","journal-title":"Mol. Carcinog."},{"issue":"12","key":"10.1016\/j.bbadis.2026.168324_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/antiox12122131","article-title":"Cosmosiin induces apoptosis in colorectal cancer by inhibiting PD-L1 expression and inducing ROS","volume":"12","author":"Han","year":"2023","journal-title":"Antioxidants"},{"issue":"1","key":"10.1016\/j.bbadis.2026.168324_bb0120","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/s41467-021-21410-1","article-title":"Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1","volume":"12","author":"Park","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbadis.2026.168324_bb0125","article-title":"Immune (cell) derived exosome mimetics (IDEM) as a treatment for ovarian cancer","volume":"8","author":"Simone","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"4","key":"10.1016\/j.bbadis.2026.168324_bb0130","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00109-022-02180-9","article-title":"EV-T synergizes with AZD5582 to overcome TRAIL resistance through concomitant suppression of cFLIP, MCL-1, and IAPs in hepatocarcinoma","volume":"100","author":"Su","year":"2022","journal-title":"J. Mol. Med."},{"issue":"11","key":"10.1016\/j.bbadis.2026.168324_bb0135","article-title":"Enhanced apoptosis: TRAIL-armed ER nanosomes induce drastically enhanced apoptosis in resistant tumor in combination with the antagonist of IAPs (AZD5582) (Adv. Healthcare Mater. 11\/2021)","volume":"10","author":"Huan","year":"2021","journal-title":"Adv. Healthc. Mater."},{"issue":"2","key":"10.1016\/j.bbadis.2026.168324_bb0140","article-title":"Sensitizing TRAIL response via differential modulation of anti- and pro-apoptotic factors by AZD5582 combined with ER nanosomal TRAIL in neuroblastoma","volume":"124","author":"Chaohong","year":"2022","journal-title":"Acta Histochem."},{"issue":"7","key":"10.1016\/j.bbadis.2026.168324_bb0145","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jcyt.2015.03.603","article-title":"Mesenchymal stromal cell delivery of full-length tumor necrosis factor-related apoptosis-inducing ligand is superior to soluble type for cancer therapy","volume":"17","author":"Yuan","year":"2015","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.bbadis.2026.168324_bb0150","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-023-01725-x","article-title":"Roles of tumor-associated macrophages in anti-PD-1\/PD-L1 immunotherapy for solid cancers","volume":"22","author":"Hao","year":"2023","journal-title":"Mol. Cancer"},{"issue":"10","key":"10.1016\/j.bbadis.2026.168324_bb0155","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1158\/2326-6066.CIR-15-0043","article-title":"Differential expression of PD-L1 between primary and metastatic sites in clear-cell renal cell carcinoma","volume":"3","author":"Marcella","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"5","key":"10.1016\/j.bbadis.2026.168324_bb0160","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.7150\/jca.29052","article-title":"PD-L1 expression patterns in tumour cells and their association with CD8+ tumour infiltrating lymphocytes in clear cell renal cell carcinoma","volume":"10","author":"Qian","year":"2019","journal-title":"J. Cancer"},{"issue":"14","key":"10.1016\/j.bbadis.2026.168324_bb0165","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1158\/1078-0432.CCR-21-4115","article-title":"A randomized phase II study of MEDI0680 in combination with Durvalumab versus Nivolumab monotherapy in patients with advanced or metastatic clear-cell renal cell carcinoma","volume":"28","author":"Voss","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"7\u20138","key":"10.1016\/j.bbadis.2026.168324_bb0170","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41417-019-0150-6","article-title":"Mechanism and therapeutic prospect of resveratrol combined with TRAIL in the treatment of renal cell carcinoma","volume":"27","author":"Zeng","year":"2020","journal-title":"Cancer Gene Ther."},{"issue":"16","key":"10.1016\/j.bbadis.2026.168324_bb0175","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.2217\/nnm-2020-0035","article-title":"RGD-decorated solid lipid nanoparticles enhance tumor targeting, penetration and anticancer effect of asiatic acid","volume":"15","author":"Tanem","year":"2020","journal-title":"Nanomedicine (Lond.)"},{"issue":"1","key":"10.1016\/j.bbadis.2026.168324_bb0180","doi-asserted-by":"crossref","DOI":"10.1515\/med-2025-1306","article-title":"Engineered RBC-derived nanovesicles functionalized with tumor-targeting ligands: a comparative study on breast cancer targeting efficiency and biocompatibility","volume":"20","author":"Yang","year":"2025","journal-title":"Open Medicine"},{"issue":"8","key":"10.1016\/j.bbadis.2026.168324_bb0185","article-title":"Monoclonal antibody-guided tumor-targeted hollow virus-like cerium oxide with oxygen self-supply for intensifying photodynamic therapy","volume":"12","author":"Mengqi","year":"2022","journal-title":"Adv. Healthc. Mater."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443926001870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443926001870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:42:54Z","timestamp":1785876174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443926001870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0925443926001870"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2026.168324","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergistic apoptosis-sensitizing effect of PD-L1 inhibitor ARB-272572 encapsulated in TRAIL-expressing extracellular vesicles for renal cell carcinoma therapy","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbadis.2026.168324","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"168324"}}